Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Skin-adverse drug reactions in the elderly: An underestimated and avoidable issue.

Annales de dermatologie et de venereologie·2025
Same author

Efficacy of upadacitinib in patients with severe alopecia areata, including baricitinib-refractory cases: A case series of 22 patients.

Journal of the American Academy of Dermatology·2025
Same author

Real-life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Bullous pemphigoid burden of disease, management and unmet therapeutic needs.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort.

Annales de dermatologie et de venereologie·2023
Same author

Lichen scrofulosorum following initiation of antitubercular treatment for tuberculous lymphadenitis.

Annales de dermatologie et de venereologie·2023
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

Related Experiment Video

Updated: Dec 22, 2025

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

848

[Pemphigus: a review].

P Joly1, C Sin

  • 1Clinique dermatologique, hôpital Charles-Nicolle, université de Rouen, 1 rue de Germont, Rouen cedex, France. Pascal.Joly@chu-rouen.fr

Annales De Dermatologie Et De Venereologie
|March 15, 2011
PubMed
Summary
This summary is machine-generated.

This systematic review found insufficient evidence to determine the best treatment for pemphigus vulgaris and foliaceus due to limited study power. Further research is needed to establish optimal therapeutic regimens for these autoimmune blistering diseases.

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.9K

Related Experiment Videos

Last Updated: Dec 22, 2025

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

848
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.9K

Area of Science:

  • Dermatology
  • Autoimmune Diseases
  • Pharmacology

Background:

  • Pemphigus is a rare autoimmune blistering disease.
  • Various treatment strategies have been explored for pemphigus.
  • Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are the primary subtypes discussed.

Purpose of the Study:

  • To systematically review and assess the efficacy and tolerance of proposed treatment regimens for pemphigus vulgaris and pemphigus foliaceus.
  • To synthesize findings from randomized controlled trials and other study designs.

Main Methods:

  • Systematic literature review of randomized controlled trials (RCTs) and uncontrolled studies.
  • Searched PubMed and Embase databases up to April 2009.
  • Analyzed data from eleven RCTs involving 421 patients (377 PV, 44 PF) and ten distinct treatment regimens.

Main Results:

  • Most studies lacked statistical power due to small sample sizes.
  • Mycophenolate mofetil showed higher efficacy than azathioprine for disease control in one study.
  • Azathioprine and cyclophosphamide demonstrated a potential corticosteroid-sparing effect.
  • No single regimen was identified as the most effective and well-tolerated.

Conclusions:

  • Current literature lacks sufficient statistical power to establish the optimal treatment for pemphigus.
  • The benefit of adding immunosuppressants to systemic corticosteroids as first-line therapy remains unclear.
  • Further high-powered studies are necessary to guide pemphigus treatment decisions.